Color enhancement: Difference between revisions

Line 1:

'''Colour enhancement''' is an intensification of ~~colours which results~~ in ~~them becoming extremely bright and vivid~~. During this experience, reds may seem “redder”, greens may seem “greener, ~~” etc~~ and all colors will likely ~~have become~~ much more distinct, ~~powerful~~, and intense ~~to look at~~ than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref><ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> At higher levels, this effect can sometimes result in seeing colours which are ~~percieved~~ as seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>

'''Colour enhancement''' is an intensification of the brightness and vividness of colors in the external environment. During this experience, reds may seem “redder”, greens may seem “greener", and all colors will likely appear much more distinct, complex, and visually intense than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref><ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> At higher levels, this effect can sometimes result in seeing colours which are perceived as surreal or seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>

Colour enhancement is often accompanied by other coinciding effects such as [[acuity enhancement]] and [[pattern recognition enhancement]].<ref name="25B_multiple"/><ref name="25C_multiple"/> It is most commonly induced under the influence of [[dosage#mild|mild]] [[dosage|dosages]] of [[psychedelic]] compounds, such as [[LSD]], [[psilocybin]], and [[mescaline]]. However, it can also occur to a lesser extent under the influence of certain [[stimulants]] and [[dissociatives]] such as [[MDMA]], [[ketamine]]<ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref>, or [[3-MeO-PCP]].

@@ Line 1: / Line 1: @@
 <onlyinclude>
-'''Colour enhancement''' is an intensification of colours which results in them becoming extremely bright and vivid. During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful, and intense to look at than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref><ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> At higher levels, this effect can sometimes result in seeing colours which are percieved as seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>
+'''Colour enhancement''' is an intensification of the brightness and vividness of colors in the external environment. During this experience, reds may seem “redder”, greens may seem “greener", and all colors will likely appear much more distinct, complex, and visually intense than they comparatively would be during everyday sober living.<ref name="DecreasedHueDiscrimination">Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349</ref><ref name="ImpossibleColours">Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref><ref>Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf</ref><ref name="25B_multiple>Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9</ref><ref name="25C_multiple">Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749</ref><ref>Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119</ref><ref>Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006</ref> At higher levels, this effect can sometimes result in seeing colours which are perceived as surreal or seemingly impossible.<ref name="DecreasedHueDiscrimination"/><ref name="ImpossibleColours"/>
 Colour enhancement is often accompanied by other coinciding effects such as [[acuity enhancement]] and [[pattern recognition enhancement]].<ref name="25B_multiple"/><ref name="25C_multiple"/> It is most commonly induced under the influence of [[dosage#mild|mild]] [[dosage|dosages]] of [[psychedelic]] compounds, such as [[LSD]], [[psilocybin]], and [[mescaline]]. However, it can also occur to a lesser extent under the influence of certain [[stimulants]] and [[dissociatives]] such as [[MDMA]], [[ketamine]]<ref>Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0</ref>, or [[3-MeO-PCP]].